血清S100B蛋白表达水平对小细胞肺癌患者脑转移风险的预测价值  

The Predictive Value of the Level of Serum S100B Protein Expression on the Risk of Brain Metastasis in Patients with Small Cell Lung Cancer

作　　者：颜波[1] 毛晓伟 张伟[1] 储天晴[1] 钟华[1] 姜丽岩[1] YAN Bo;MAO Xiaowei;ZHANG Wei(Shanghai Chest Hospital of Shanghai Jiaotong University,Shanghai 200030,China)

机构地区：[1]上海交通大学附属胸科医院呼吸内科,上海200030

出　　处：《河北医学》2018年第4期591-597,共7页Hebei Medicine

摘　　要：目的:探索血清S100B蛋白表达水平对于小细胞肺癌(Small Cell Lung Cancer,SCLC)患者脑转移风险的预测价值以及与SCLC患者临床病理特征的关系。方法:选择20例脑转移SCLC患者和24例无脑转移SCLC患者,同时纳入16例术后SCLC患者作为对照组。使用免疫酶吸附法(Enzyme Linked Immunosorbent Assay Kit,ELISA)检测三组患者血清S100B蛋白的表达水平。结果:与SCLC无脑转移患者和术后SCLC对照组相比,SCLC脑转移患者血清S100B蛋白水平均明显升高(均P<0.001)。受试者工作特征曲线(Receiver Operating Characteristic,ROC)表明血清S100B蛋白水平对SCLC患者脑转移风险具有较高的预测价值(SCLC脑转移患者组vs.SCLC无脑转移患者组:曲线下面积(Area Under Curve,AUC)0.840(95%CI:0.721~0.958);SCLC脑转移患者组vs.术后SCLC对照组:AUC 0.906(95%CI:0.811~1.000))。单元、多元逻辑回归分析显示,高水平血清S100B蛋白是SCLC患者脑转移风险的独立预测因素(P=0.025)。此外,在SCLC脑转移患者组中,血清S100B水平与N分期呈正相关(P=0.019)。Spearman秩相关分析显示在SCLC脑转移患者中血清S100B蛋白水平与神经元特异性烯醇化酶(Neuron Specific Enolase,NSE)呈正相关(r=0.508,P=0.022)。结论:血清S100B蛋白水平具有作为预测SCLC患者脑转移风险血清学标志物的潜能,且与SCLC脑转移患者N分期和血清NSE水平呈正相关。Objective:To evaluate the predictive value of serum S100B expression in brain metastasis risk for patients with small cell lung cancer(SCLC)and its association with clinicopathological characteristics of SCLC patients.Methods:20 SCLC patients with brain metastases,24 SCLC patients without brain metastases and 16 post-operative SCLC patients as control group were enrolled in this case-control study.The serum levels of S100B in three groups were detected by ELISA.Results:Serum S100B levels in SCLC patients with brain metastases were markedly increased compared with SCLC patients without brain metastasis and postoperative SCLC patients(all P<0.001).Receiver Operating Characteristic(ROC)showed that serum S100B level had a good predictive value for brain metastasis in SCLC patients(SCLC patients with brain metastases vs.SCLC patients without brain metastases:AUC 0.840(95%CI:0.721~0.958);SCLC patients with brain metastases vs.post-operative SCLC patients:AUC 0.906(95%CI:0.811~1.000)).Multivariate regression analysis displayed that high level of serum S100B was an independent factor in predicting brain metastasis risk in SCLC patients(P=0.025).In addition,serum S100B level was positive associated with N stage in SCLC patients with brain metastases(P=0.019).Spearman rank correlation analysis revealed that serum S100B level was positively correlated with Neuron Specific Enolase(NSE)in SCLC patients with brain metastases(r=0.508,P=0.022).Conclusion:Serum S100B could be a promising biomarker of brain metastasis risk in SCLC patients,and it is positively correlated with N stage and NSE level in SCLC patients with brain metastasis.

关 键 词：小细胞肺癌 脑转移 S100B 

分 类 号：R734.2[医药卫生—肿瘤]